New Cancer Drug Stops Disease in 85% of Patients, Sparking a 10% Stock Jump for J&J’s $2.6 Billion Partner

The world of clinical trials, constantly scrutinizing new therapies for advanced diseases, recently witnessed significant developments in oncology, highlighted by Nanobiotix's radiotherapy-activated cancer drug, JNJ-1900. This drug, previously known as NBTXR3